2016 FY Results Announcements and Analysts Briefing
Filed with ASX · · 42 pages · English
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016. After excluding the financials relating to the Novartis influenza vaccines business acquired during the year, underlying1 NPAT grew 5% and earnings per share (EPS) grew 7% on a constant currency (CC)2 basis. HIGHLIGHTS Financial • Revenue US$6,129 million o Und
Earlier from CSL
- AFSTYLA (rFVIII-Single Chain) FDA approval
- Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval
- IDELVION(R) (rFIX-FP) - European Commission Approval
- CSL to acquire Novartis influenza vaccine business
- Chairman`s Address to Shareholders
Later from CSL
- FDA Accepts BLA for Hereditary Angioedema Therapy
- Afstyla CHMP Recommendation
- Positive Results from CSL112 Phase 2b Trial
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- FY2017 Profit Upgrade
Follow CSL into a list and get an email when it puts out news.
Follow CSL